FDA approves targeted therapy for type 1 narcolepsy

The FDA has authorized Orzeyful, a medication that mimics the missing neurochemical orexin in patients with type 1 narcolepsy. Late stage clinical trials showed significant improvements in maintaining daytime wakefulness compared to existing options.